Patents by Inventor Alan P. Kozikowski

Alan P. Kozikowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200115350
    Abstract: The present disclosure provides compounds represented by Formula (I): and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 16, 2020
    Inventors: ALEJANDRO VILLAGRA, Alan P. KOZIKOWSKI, Sida SHEN
  • Patent number: 10227295
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: March 12, 2019
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
  • Publication number: 20170369428
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 28, 2017
    Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
  • Patent number: 9751832
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 5, 2017
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of the University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
  • Publication number: 20160185716
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 30, 2016
    Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Lagra, Karrune V. Woan
  • Publication number: 20150306069
    Abstract: The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Philip P. Connell, Brian Budke, Jay H. Kalin, Michal Pawlowski, Alan P. Kozikowski
  • Publication number: 20150079001
    Abstract: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
    Type: Application
    Filed: May 22, 2014
    Publication date: March 19, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN GILBERT POMPER, JIAZHONG ZHANG, ALAN P. KOZIKOWSKI, JOHN L. MUSACHIO
  • Patent number: 8748463
    Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 10, 2014
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
  • Patent number: 8653278
    Abstract: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising an HDAC inhibitor of the invention.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: February 18, 2014
    Assignees: Georgetown University, The Board of Trustees of the University of Illinois
    Inventors: Alan P. Kozikowski, Mira Jung, Anatoly Dritschilo, Arsen Gaysin, Pavel A. Petukhov, Werner Tueckmantel, Hongbin Yuan, Yufeng Chen
  • Patent number: 8609721
    Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: December 17, 2013
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Jarda T. Wroblewski, Fajun Nan
  • Publication number: 20130184313
    Abstract: The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 18, 2013
    Applicants: The Board of Trustees of the University of Illinois, PsychoGenics, Inc.
    Inventors: Jayaraman Chandrasekhar, Alan P. Kozikowski, Jianhua Liu, Werner Tueckmantel, Joel R. Walker, Po-wai Yuen
  • Patent number: 8445684
    Abstract: The invention relates to pyridinyl nicotinic acetylcholine receptor ligands, compositions comprising an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand and methods to treat or prevent a condition, such as depression and nicotine dependence, comprising administering to an animal in need thereof an effective amount of a pyridinyl nicotinic acetylcholine receptor ligand.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: May 21, 2013
    Assignees: PsycoGenics Inc., The Board of Trustee of the University of IL
    Inventors: Jayaraman Chandrasekhar, Alan P. Kozikowski, Jianhua Liu, Werner Tueckmantel, Joel R. Walker, Po-wai Yuen
  • Publication number: 20130065963
    Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Application
    Filed: July 17, 2012
    Publication date: March 14, 2013
    Applicant: Georgetown University
    Inventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
  • Publication number: 20120276007
    Abstract: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 1, 2012
    Applicants: Georgetown University, The Johns Hopkins University
    Inventors: Martin Gilbert Pomper, Jiazhong Zhang, John L. Musachio, Alan P. Kozikowski
  • Patent number: 8227634
    Abstract: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: July 24, 2012
    Inventors: Martin Gilbert Pomper, Jiazhong Zhang, Alan P. Kozikowski, John L. Musachio
  • Patent number: 8222451
    Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: July 17, 2012
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
  • Patent number: 8207216
    Abstract: Compounds of formula: and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: June 26, 2012
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Alan P. Kozikowski, Irina Gaysina
  • Patent number: 8153657
    Abstract: One aspect of the invention relates to piperidine compounds that are useful as inhibitors of monoamine transporters. The invention also relates to pharmaceutical compositions, comprising a piperidine compound of the invention. Another aspect of the present invention relates to the use of the aforementioned compounds in a method of treating a disorder of the central nervous system in a mammal.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: April 10, 2012
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Jia Zhou
  • Patent number: 8067600
    Abstract: One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: November 29, 2011
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Bin Chen
  • Patent number: 8044103
    Abstract: The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: October 25, 2011
    Assignee: Georgetown University
    Inventors: Alan P. Kozikowski, Alan I. Faden, Gian Luca Araldi